OraSure Technologies (NASDAQ:OSUR) Announces Earnings Results

OraSure Technologies (NASDAQ:OSURGet Free Report) issued its earnings results on Wednesday. The medical instruments supplier reported $0.04 EPS for the quarter, hitting the consensus estimate of $0.04, Briefing.com reports. OraSure Technologies had a return on equity of 7.68% and a net margin of 7.50%. The firm had revenue of $54.10 million during the quarter, compared to the consensus estimate of $52.27 million. During the same quarter in the previous year, the firm earned $0.37 earnings per share. The business’s quarterly revenue was down 65.1% on a year-over-year basis. OraSure Technologies updated its Q2 2024 guidance to EPS.

OraSure Technologies Stock Down 3.7 %

NASDAQ OSUR opened at $4.86 on Friday. The stock has a fifty day simple moving average of $5.98 and a 200 day simple moving average of $6.78. OraSure Technologies has a twelve month low of $4.38 and a twelve month high of $8.45. The company has a market capitalization of $371.84 million, a price-to-earnings ratio of 16.20 and a beta of 0.23.

Analyst Upgrades and Downgrades

OSUR has been the subject of several research analyst reports. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday. Evercore ISI dropped their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $6.38.

Check Out Our Latest Stock Analysis on OSUR

OraSure Technologies Company Profile

(Get Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Articles

Earnings History for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.